Our immunohistochemistry results revealed increased CDK5 expression levels in HCC patients with tumor metastasis, vascular invasion, portal vein tumor embolus, moderate differentiation and higher clinical TNM stages. This evidence concerns the gene CDK5 and hepatocellular carcinoma.